Menopausal hormone therapy and cardiovascular disease risk: Utility of biomarkers and clinical factors for risk stratification

Clinical Chemistry

Volumn 60, Issue 1, 2014, Pages 68-77

  Bassuk, Shari S ^a   Manson, Joann E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO;

BLOOD SAMPLING; BRAIN ISCHEMIA; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FRAMINGHAM RISK SCORE; HEART FAILURE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MENOPAUSAL SYNDROME; MENOPAUSE; METABOLIC SYNDROME X; PERSONALIZED MEDICINE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SERUM; VENOUS THROMBOEMBOLISM;

EID: 84891793742     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.202556     Document Type: Review

References (53)

1. North American Menopause Society. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012;19: 257-71.
2. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:S1- S66.
3. Manson JE, Bassuk SS. The menopause transition and postmenopausal hormone therapy. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jamison JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2011.
4. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012;120: 595-603.
5. Manson JE. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metabolism 2013; 62 Suppl 1:S15-19.
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-33. (Pubitemid 34761611)
7. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-12. (Pubitemid 38489892)
8. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310: 1353-68.
9. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13. (Pubitemid 28502636)
10. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 49-57. (Pubitemid 34705518)
11. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96. (Pubitemid 30244167)
12. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 58-66. (Pubitemid 34705519)
13. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523-34. (Pubitemid 36951364)
14. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and the risk of coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357-65. (Pubitemid 43244325)
15. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Effects of postmenopausal hormone therapy on cardiovascular disease by age and years since menopause. JAMA 2007;297: 1465-77. (Pubitemid 46556472)
16. Rossouw JE, Cushman M, Greenland P, Lloyd- Jones DM, Bray P, Kooperberg C, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 2008;168: 2245-53.
17. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289: 2673-84. (Pubitemid 37430138)
18. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113: 2425-34. (Pubitemid 43948050)
19. Kooperberg C, Cushman M, Hsia J, Robinson JG, Aragaki AK, Lynch JK, et al. Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials 2007;2:e28.
20. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292: 1573-80. (Pubitemid 39314963)
21. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166: 772-80.
22. Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the Heart and Estrogen/ Progestin Replacement Study: lessons learned. Circulation 2002;105: 917-22. (Pubitemid 34184567)
23. Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105: 2962-7. (Pubitemid 34693827)
24. Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hor- mone therapy in postmenopausal women. Menopause 2009;16: 639-43.
25. Manson JE, Allison MA, Rossouw JE, Carr J, Langer RD, Hsia J, et al. Estrogen therapy and coronary artery calcification. N Engl J Med 2007; 356: 2591-602. (Pubitemid 46961004)
26. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133: 933-41. (Pubitemid 32003509)
27. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15: 35-44. (Pubitemid 43192860)
28. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21: 363-6.
29. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, et al. Main morbidities recorded in the Women's International Study of long Duration Oestrogen after Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239.
30. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.
31. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53: 605-19. (Pubitemid 34175253)
32. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343: 522-9. (Pubitemid 30650747)
33. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349: 535-45. (Pubitemid 36951365)
34. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288: 2432-40. (Pubitemid 35340539)
35. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis : a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21: 262-8. (Pubitemid 32125376)
36. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, doubleblind, placebo-controlled trial. Annual Intern Med 2001;135: 939-53. (Pubitemid 33131615)
37. Harman SM. Effects of oral conjugated estrogen or transdermal estradiol plus oral progesterone treatment on common carotid artery intima media thickness (CIMT) & coronary artery calcium (CAC) in menopausal women: initial results from the Kronos Early Estrogen Prevention Study (KEEPS) [Abstract]. Menopause 2012;19:1365.
38. Kronos Early Estrogen Prevention Study. News: frequently asked questions. http://www. keepstudy.org/news/keeps-faq.cfm (Accessed December 2013).
39. ELITE: Early Versus Late Intervention Trial With Estrogen. Hodis HN, principal investigator. http:// clinicaltrials.gov/ct/show/NCT00114517?order-1 (Accessed December 2013).
40. Canonico M, Plu-Bureau G, O'Sullivan MJ, Stefanick ML, Cochrane B, Scarabin PY, Manson JE. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative hormone therapy clinical trials. Menopause [Epub 2013 Jun 10].
41. Bray PF, Larson JC, LaCroix AZ, Manson J, Limacher MC, Rossouw JE, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008;101: 1599-605.
42. Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013;20: 254-60.
43. Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C, et al. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol 2011;31: 464-9.
44. Rossouw JE, Prentice RL, Manson JE, Aragaki AK, Hsia J, Martin LW, et al. Relationships of coronary heart disease with 27-hydroxycholesterol, lowdensity lipoprotein cholesterol, and menopausal hormone therapy. Circulation 2012;126: 1577-86.
45. Rossouw JE, Johnson KC, Pettinger M, Cushman M, Sandset PM, Kuller L, et al. Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. Stroke 2012;43: 952-7.
46. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283: 1845-52. (Pubitemid 30207621)
47. Prentice RL, Paczesny S, Aragaki A, Amon LM, Chen L, Pitteri SJ, et al. Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by indepth plasma proteome profiling. Genome Med 2010;2:48.
48. Huang Y, Ballinger DG, Stokowski R, Beilharz E, Robinson JG, Liu S, et al. Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. Genome Med 2012;4:57.
49. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115: 840-5. (Pubitemid 46294724)
50. Canonico M, Fournier A, Carcaillon L, Olie V, Plu-Bureau G, Oger E, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30: 340-5.
51. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008; 168: 861-6. (Pubitemid 351620088)
52. Prentice RL, Huang Y, Hinds DA, Peters U, Pettinger M, Cox DR, et al. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18: 3079-85.
53. Mackey RH, Fanelli TJ, Modugno F, Cauley JA, McTigue KM, Brooks MM, et al. Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. Cancer Epidemiol Biomarkers Prev 2012;21: 2022-32.